Verity A Saunders

2.5k total citations
62 papers, 1.6k citations indexed

About

Verity A Saunders is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Verity A Saunders has authored 62 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Hematology, 45 papers in Genetics and 21 papers in Rheumatology. Recurrent topics in Verity A Saunders's work include Chronic Myeloid Leukemia Treatments (54 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Eosinophilic Disorders and Syndromes (21 papers). Verity A Saunders is often cited by papers focused on Chronic Myeloid Leukemia Treatments (54 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Eosinophilic Disorders and Syndromes (21 papers). Verity A Saunders collaborates with scholars based in Australia, United States and Switzerland. Verity A Saunders's co-authors include Timothy P. Hughes, Deborah L. White, Phuong Dang, Jane R. Engler, Paul W. Manley, Andrew C.W. Zannettino, Stephanie Zrim, Amity Frede, Antony C. Cambareri and Susan Branford and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Verity A Saunders

59 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Verity A Saunders Australia 19 1.2k 1.0k 567 332 250 62 1.6k
Devendra Hiwase Australia 20 944 0.8× 489 0.5× 174 0.3× 296 0.9× 378 1.5× 107 1.3k
Pascale Cony‐Makhoul France 24 1.3k 1.0× 864 0.9× 502 0.9× 318 1.0× 257 1.0× 76 1.5k
Ghayas C. Issa United States 24 1.5k 1.2× 631 0.6× 207 0.4× 504 1.5× 652 2.6× 146 2.1k
Kara Johnson United States 15 607 0.5× 472 0.5× 337 0.6× 114 0.3× 313 1.3× 19 978
Eva Barragán Spain 24 936 0.7× 283 0.3× 74 0.1× 210 0.6× 1.1k 4.3× 92 1.7k
N. Bekele United States 11 385 0.3× 314 0.3× 186 0.3× 203 0.6× 481 1.9× 23 1.0k
M Beran United States 14 407 0.3× 302 0.3× 113 0.2× 209 0.6× 335 1.3× 18 812
Elisabeth Oppliger Leibundgut Switzerland 16 412 0.3× 311 0.3× 102 0.2× 178 0.5× 480 1.9× 38 897
Carolyn Grove Australia 14 772 0.6× 295 0.3× 36 0.1× 128 0.4× 721 2.9× 29 1.3k
Sylvain Thépot France 19 1.0k 0.8× 408 0.4× 45 0.1× 200 0.6× 542 2.2× 81 1.3k

Countries citing papers authored by Verity A Saunders

Since Specialization
Citations

This map shows the geographic impact of Verity A Saunders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Verity A Saunders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Verity A Saunders more than expected).

Fields of papers citing papers by Verity A Saunders

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Verity A Saunders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Verity A Saunders. The network helps show where Verity A Saunders may publish in the future.

Co-authorship network of co-authors of Verity A Saunders

This figure shows the co-authorship network connecting the top 25 collaborators of Verity A Saunders. A scholar is included among the top collaborators of Verity A Saunders based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Verity A Saunders. Verity A Saunders is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kok, Chung Hoow, Yazad Irani, Jade Clarson, et al.. (2024). CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib. PubMed. 1(2). 100014–100014. 1 indexed citations
2.
3.
4.
Kok, Chung Hoow, Verity A Saunders, Phuong Dang, et al.. (2023). Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib. Blood Cancer Journal. 13(1). 143–143. 1 indexed citations
5.
Kutyna, Monika, et al.. (2023). Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines. International Journal of Molecular Sciences. 24(4). 3553–3553. 3 indexed citations
6.
Shanmuganathan, Naranie, Carol Wadham, Daniel Thomson, et al.. (2022). RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia. Journal of Molecular Diagnostics. 24(7). 803–822. 5 indexed citations
7.
Schmitz, Ulf, Jaynish S. Shah, Bijay Dhungel, et al.. (2020). Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients. Cancers. 12(12). 3738–3738. 10 indexed citations
8.
Kok, Chung Hoow, David T Yeung, Lu Liu, et al.. (2019). Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Advances. 3(10). 1610–1621. 23 indexed citations
9.
Pagani, Ilaria S., Phuong Dang, Verity A Saunders, et al.. (2019). Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia. 34(4). 1052–1061. 31 indexed citations
10.
Ross, David M., Ilaria S. Pagani, Naranie Shanmuganathan, et al.. (2018). Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia. 32(12). 2572–2579. 56 indexed citations
11.
Pagani, Ilaria S., Phuong Dang, Jarrad M. Goyne, et al.. (2018). BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica. 103(12). 2026–2032. 25 indexed citations
12.
Pagani, Ilaria S., Chung Hoow Kok, Verity A Saunders, et al.. (2017). A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia. Journal of Molecular Diagnostics. 19(5). 711–721. 6 indexed citations
13.
Kok, Chung Hoow, Verity A Saunders, Jarrad M. Goyne, et al.. (2017). Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica. 102(5). 843–853. 11 indexed citations
14.
Saunders, Verity A, Lu Liu, Laura N Eadie, et al.. (2016). A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells. Blood. 128(22). 1121–1121. 2 indexed citations
15.
Hiwase, Devendra, Deborah L. White, Jason A. Powell, et al.. (2010). Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia. 24(4). 771–778. 37 indexed citations
16.
Engler, Jane R., Amity Frede, Verity A Saunders, et al.. (2010). The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. Blood. 116(15). 2776–2778. 19 indexed citations
17.
18.
White, Deborah L., Verity A Saunders, Thea Kalebic, & Timothy P. Hughes. (2008). The IC50 Assay Is Predictive of Molecular Response, and Indicative of Optimal Dose in De-Novo CML Patients.. Blood. 112(11). 1109–1109. 6 indexed citations
19.
White, Deborah L., Verity A Saunders, Phuong Dang, et al.. (2007). Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 110(12). 4064–4072. 244 indexed citations
20.
White, Deborah L., et al.. (2007). Proton pump inhibitors interact with transport of both imatinib and nilotinib.. Cancer Research. 67. 1635–1635. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Devendra Hiwase Breakdown of academic impact, for papers by Pascale Cony‐Makhoul Breakdown of academic impact, for papers by Ghayas C. Issa Breakdown of academic impact, for papers by Kara Johnson Breakdown of academic impact, for papers by Eva Barragán Breakdown of academic impact, for papers by N. Bekele Breakdown of academic impact, for papers by M Beran Breakdown of academic impact, for papers by Elisabeth Oppliger Leibundgut Breakdown of academic impact, for papers by Carolyn Grove Breakdown of academic impact, for papers by Sylvain Thépot
Rankless by CCL
2026